Tumor treatment device plus chemo for locally advanced pancreatic cancer
Part of Cancer, Digestive system clinical trials.
This trial tests whether a home-wearable tumor-treating device (Tumor Treating Fields) combined with gemcitabine and albumin-bound paclitaxel works better as first treatment for locally advanced pancreatic cancer. It may help by targeting cancer cells while also using standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 to 75 years old, and you have pancreatic adenocarcinoma confirmed by pathology (biopsy/cytology).
- Your cancer is “locally advanced” but not spread to distant organs (no distant metastasis).
- You have at least one measurable tumor spot on scans, and you are well enough to do daily activities (ECOG 0–1).
- You must be able to receive both chemotherapy medicines: gemcitabine and albumin-bound paclitaxel.
- You must be able to apply and run the tumor-treating device yourself (or with help from nursing staff).
- No pregnancy or breastfeeding; you must use effective birth control for the time period specified by the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two different chemotherapy combinations, each paired with immunotherapy and radiation, as the first treatment for locally advanced pancreatic cancer. It aims to see which combination works better.
This trial tests how safe and effective nab-paclitaxel plus gemcitabine chemo is when paired with proton radiation for locally advanced pancreatic cancer that cannot be removed with surgery. It may help shrink the tumor and improve local control.
This trial studies a chemotherapy combination (albumin-bound paclitaxel and gemcitabine) as first treatment for pancreatic cancer that cannot be removed by surgery. It aims to improve outcomes by testing how well this treatment works in people with locally advanced or metastatic disease.
This trial studies NovoTTF-200T(P), a portable treatment device, combined with standard chemotherapy (gemcitabine and nab-paclitaxel) for people with resectable pancreatic adenocarcinoma. It aims to improve treatment results by trying this combination before surgery.
This trial tests whether combining targeted radiation with an at-home “tumor treating fields” device can better control locally advanced pancreatic cancer. It may help by attacking cancer cells in more than one way after prior chemotherapy.
This trial tests a new drug called IBI343 combined with standard chemotherapy for people with advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
Hear when a new Locally Advanced Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.